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a randomized trial of the early introduction of allergenic solids
into the infant diet from 3 months of age. The intervention effect
did not reach statistical significance in the intention-to-treat
analysis of the primary outcome.
Objective: We sought to determine whether infants at high risk
of developing a food allergy benefited from early introduction.
Methods: A secondary intention-to-treat analysis was
performed of 3 groups: nonwhite infants; infants with visible
eczema at enrollment, with severity determined by SCORAD;
and infants with enrollment food sensitization (specific IgE >_0.1
kU/L).
Results: Among infants with sensitization to 1 or more foods at
enrollment (>_0.1 kU/L), early introduction group (EIG) infants
developed significantly less food allergy to 1 or more foods than
standard introduction group (SIG) infants (SIG, 34.2%; EIG,
19.2%; P 5 .03), and among infants with sensitization to egg at
enrollment, EIG infants developed less egg allergy (SIG, 48.6%;
EIG, 20.0%; P 5 .01). Similarly, among infants with moderate
SCORAD (15-<40) at enrollment, EIG infants developed
significantly less food allergy to 1 or more foods (SIG, 46.7%;
EIG, 22.6%; P 5 .048) and less egg allergy (SIG, 43.3%; EIG,
16.1%; P 5 .02).
Conclusion: Early introduction was effective in preventing the
development of food allergy in specific groups of infants at high
risk of developing food allergy: those sensitized to egg or to any
food at enrollment and those with eczema of increasing severity
at enrollment. This efficacy occurred despite low adherence to
the early introduction regimen. This has significant implications
for the new national infant feeding recommendations that are
emerging around the world. (J Allergy Clin Immunol
2019;144:1606-14.)
Key words: Food allergy, diet, allergens, infancy, breastfeeding,
randomized controlled trial, adherence
The Enquiring About Tolerance (EAT) Study was conceived to
reduce the burden of food allergies through early oral tolerance
induction to specific food antigens.1 Rates of adherence to the
challenging early introduction protocol were low, with 43% of
adherence-evaluable EIG infants (34% of all EIG infants)
consuming the per-protocol consumption threshold of
recommended allergenic foods. This level of adherence was
associated with a nonsignificant reduction in IgE-mediated food
allergy to 1 or more of the 6 intervention foods.2
At a food-specific level, adherence varied, with some foods
being easier to consume than others: egg at 43.1% and peanut at
61.9%.1 In the intention-to-treat analysis both foods showed
nonsignificant reductions in allergy prevalence of 31% and 51%
for egg and peanut, respectively.2 Per-protocol effects were
significantly stronger and in keeping with Learning Early About
Peanut (LEAP) allergy study effect estimates.3 However,
per-protocol analyses are susceptible to bias depending on what
factors determined adherence in the study.
Well-recognized factors that render an infant from the general
population to be at greater risk of a food allergy include nonwhite
ethnicity,4 early-onset eczema,5 and early-onset sensitization to a
food.6,7 In the EAT study we have previously confirmed that
nonwhite ethnicity (odds ratio [OR], 2.09; 95% CI, 1.19-3.66;
P 5 .01) and enrollment visible eczema (3 months of age; OR,6.09; 95% CI, 3.67-10.1; P < .001) were both significantly
associated with developing a food allergy.2
At the time of publication of the EAT study’s principal results,
the enrollment sensitization data available were the skin prick test
results, which took place, by design, only in the early introduction
group (EIG). Enrollment skin prick test sensitization (any positive
wheal response to >_1 foods) was significantly associated with
having a food allergy in the EIG (OR, 5.71; 95% CI, 1.99-16.3;
P 5 .001).
The absence of comparator data from the standard introduction
group (SIG) precluded comparisons between the 2 groups in
terms of efficacy of the EAT intervention in infants sensitized at
enrollment. Following publication of the primary EAT study
findings, we secured funding to process IgE results for this large
sample set. Infants were defined as sensitized at enrollment if they
had specific IgE antibodies present to 1 or more of the 6 allergenic
foods at enrollment at 3 months of age.
We now present the findings of the efficacy of the EAT study in
these groups of infants at high risk of developing a food allergy.
The efficacy analysis of the subgroup of infants with eczema at
enrollment was stipulated in the EAT study protocol a priori. The
efficacy of the EAT study intervention in nonwhite participants
and those sensitized at enrollment are secondary analyses.METHODS
Participants
One thousand three hundred and three 3-month-old infants were recruited
from the general population in England and Wales through direct advertising
and enrolled between November 2, 2009, and July 30, 2012. The CONSORT
figure for the EAT study is shown in Fig E1 in this article’s Online Repository
at www.jacionline.org. Full methodological details, the trial protocol, and the
statistical analysis plan (original documents and final versions, with summary
of all changes made to both documents) and other CONSORT information for
the primary outcome of the EAT study are published elsewhere.1,2 The trial
was registered with the ISRCTN (registration no. 14254740). All participants
were healthy, exclusively breastfed, and born at term (>_37 weeks’ gestation).
Ethnic origin of the child was based on self-defined parental ethnicity coded
by the classification used in the 2001 UK Census.8 Ethical approval for the
EAT study was provided by St Thomas’ Hospital REC (REC reference
08/H0802/93), and informed consent was obtained from the parents of all
children enrolled in the study.EAT study intervention
In brief, participants were randomized to the SIG or EIG. The SIG was
asked to exclusively breastfeed to around 6 months of age. Allergenic food
introduction beyond this point was at parental discretion. EIG infants
continued to breastfeed while sequentially introducing 6 allergenic foods:
cow’s milk yogurt; then peanut, hard-boiled egg, sesame, and whitefish (cod)
in a random order; and finally wheat. By week 6, EIG infants were ideally
consuming the required amount of all 6 allergenic foods each week.
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Scheduled clinic visits took place at enrollment and 1 and 3 years of age.
All children were examined for eczema at all 3 clinic visits using the UK
Diagnostic Criteria–based photographic protocol of the International Study of
Asthma and Allergies in Childhood Phase Two.9 Disease severity was deter-
mined by using the Scoring Atopic Dermatitis (SCORAD) index.10 SCORAD
was categorized as mild (<15), moderate (15 to <40), and severe (>_40).10Sensitization
Only infants in the EIG underwent skin prick tests at enrollment. SIG
participants did not undergo skin prick tests at enrollment because this would
likely have influenced a family’s decision on when to introduce allergenic
foods into their child’s diet. The desire was for SIG participants to introduce
allergenic foods at the same time that they would have done if they had not
been participating in the study.
In contrast, blood sampling was attempted on all infants at enrollment.
Samples were then stored until completion of the study. IgE levels to each of
the 6 individual foods were thenmeasured with the ImmunoCAP assay system
(Phadia, Uppsala, Sweden).Primary outcome
All children with a positive skin prick test response to 1 or more of the
6 intervention foods at the 1-year and/or 3-year assessments or a history of
a positive challenge at less than 1 year of age were considered for a food
challenge. The decision to challenge and the timing and type of challenge
undertaken were based on the participant’s study group and frequency of
consumption status.2 In the EAT study the primary outcome was allergy
proven by double-blind challenge where possible, to 1 or more of the 6
early introduction foods. One thousand one hundred seventy-three
(90.0%) of the participants attended the final 3-year visit within the sched-
uled visit window (by 4 years of age), and the primary outcome could be
determined in 1178 (90.4%) participants. Although the study was not
specifically powered to look at individual food allergy outcomes, there
were sufficient cases of peanut and egg allergy to analyze these outcomes.
There were insufficient cases of allergy to any of the other 4 foods (ses-
ame, wheat, cow’s milk, and fish) to undertake subgroup analyses for these
foods.
Diagnostic cut-off values for predicting food allergy based on skin prick
test results have been shown to have lower thresholds in younger children.11
Safety was paramount in the EAT study and, given that the presence of a
positive skin prick test response at enrollment resulted in a food challenge
being undertaken before home consumption was allowed, a wheal of any
size was deemed positive to minimize false-negative test results. Although
IgE sensitization data are presented by using a standard threshold of
0.35 kU/L or greater, given the very young age, a lower threshold of
0.1 kU/L or greater was used for the primary analyses of food allergy
outcomes. For the outcome of food allergy to 1 or more of the 6 early
introduction foods, sensitization at enrollment was defined as sensitization
of 0.1 kU/L or greater to any 1 of the 6 foods. For peanut and egg allergy
outcomes, sensitization at enrollment refers to sensitization of 0.1 kU/L or
greater to the specific food.Statistical analyses
Chi-squared tests or Fisher exact tests (where appropriate) were
undertaken for unadjusted analyses. A formal test for interaction was
undertaken in a logistical model, including study group and sensitization
to 1 or more foods (for the outcome of allergy to any food) or sensitization
to a specific food (for the outcome of food allergy to that food). An
interaction term was included between the study group and sensitization
variables. Analyses were undertaken with Stata 15 software (StataCorp,
College Station, Tex). The EAT data set (ITN900AD) is available through
TrialShare, a public Web site managed by the Immune Tolerance Network
(www.itntrialshare.org).RESULTS
Infants were enrolled in the EAT study at 3 months of age
(mean age at enrollment, 14.7 weeks).Eczema
Visible eczema was present at the enrollment visit in 24.3%
(317/1302) of participants. Of the 317 infants with eczema, most
was mild: mild SCORAD (<15) in 76.3% (n 5 242), moderate
SCORAD (15 to <40) in 20.8% (n 5 66), and severe SCORAD
(>_40) in 2.8% (n 5 9).
Infants with visible eczema were significantly more likely to
have enrollment IgE levels exceeding the 0.1 kU/L threshold (no
eczema, 10.0%; visible eczema, 32.2%; P < .001). Furthermore,
among those with visible eczema, the likelihood of exceeding
the 0.1 kU/L threshold showed a dose response with SCORAD
severity: mild (SCORAD <15) 22.4%, moderate (SCORAD
15 to <40) 60.0%, and severe (SCORAD >_40) 88.9% (P < .001).Ethnicity
One thousand one hundred four (84.7%) of the enrolled infants
were white, and 199 were nonwhite (15.3%). The nonwhite group
consisted of 119 infants of mixed ethnicity (9.1%) and 80 (6.1%)
black, Asian, or Chinese infants. Enrollment sensitization was
very strongly associated with ethnicity. Sensitization at enroll-
ment to 1 or more foods exceeding the 0.1 kU/L threshold was
present in 12.3% of white participants, 22.9% participants of
mixed ethnicity, and 48.6% of black, Asian, or Chinese
participants (P < .001). Enrollment sensitization based on skin
prick test responses in the EIG was also strongly associated
with ethnicity: 3.6% of white participants had positive skin prick
test responses to 1 or more foods (wheal of any), as did 4.2% of
participants ofmixed ethnicity and 23.4% of participants of black,
Asian, or Chinese ethnicity (P < .001).Sensitization
Skin prick tests were undertaken in all 652 EIG infants
(Table I). Specific IgE levels were measured successfully in
1170 participants (SIG, 89% [577/651]; EIG, 91% [593/652]).
Enrollment sensitization was more frequent when defined by
specific IgE results (Table I). Of EIG participants, 5.1% were
sensitized to 1 or more foods on skin prick tests (>0 mm wheal)
compared with 5.7% using a specific IgE threshold of
0.35 kU/L or greater and 15.7% using a threshold of 0.1 kU/L
or greater. There were no significant baseline differences between
either group on specific IgE testing at either threshold level for
any food or for individual foods (Table I).
Sensitization rates varied significantly by food in both forms of
testing. Egg results were most commonly positive, whereas in
contrast, not 1 infant was sensitized to fish based on specific IgE
levels or skin prick test responses. Milk sensitization was more
common than peanut sensitization on both skin prick testing and
specific IgE measurements.Adherence to the early introduction regimen
among groups at high risk of food allergy
In univariate analyses EIG participants with eczema were less
likely to adhere to the early introduction regimen (no eczema,
TABLE I. Enrollment SPT and specific IgE sensitization data from the EAT study
Peanut Egg Milk Sesame Fish Wheat Any food
SPT >0 mm
EIG 1.2% (8/652) 3.7% (24/652) 1.5% (10/652) 0% (0/652) 0% (0/652) 0.2% (1/652) 5.1% (33/652)
Specific IgE (kU/L)
Mean 0.07 0.20 0.11 0.06 0.004 0.07
Median 0.03 0.01 0.02 0.06 0.00 0.04
Range 0-11.60 0-42.22 0-57.49 0-0.33 0-0.09 0-12.91
Specific IgE >_0.1 kU/L
All participants 3.6% (42/1166) 6.7% (78/1170) 6.0% (70/1169) 2.0% (23/1151) 0% (0/1164) 4.3% (50/1165) 15.6% (182/1170)
SIG 3.1% (18/576) 7.3% (42/577) 6.6% (38/576) 1.4% (8/572) 0% (0/575) 4.3% (25/576) 15.4% (89/577)
EIG 4.1% (24/590) 6.1% (36/593) 5.4% (32/593) 2.6% (15/579) 0% (0/589) 4.2% (25/589) 15.7% (93/593)
Specific IgE >_0.35 kU/L
All participants 1.6% (19/1166) 3.9% (45/1170) 2.8% (33/1169) 0% (0/1151) 0% (0/1164) 0.9% (10/1165) 6.4% (74/1170)
SIG 1.6% (9/576) 4.7% (27/577) 3.3% (19/576) 0% (0/572) 0% (0/575) 1.0% (6/589) 6.9% (40/577)
EIG 1.7% (10/590) 3.0% (18/593) 2.4% (14/593) 0% (0/579) 0% (0/589) 0.7% (4/576) 5.7% (34/593)
Specific IgE levels were measured in 1170 children. However, some infants had very small amounts of serum obtained, and levels for all 6 individual foods could not be measured.
Hence the denominator for individual foods varies (ranging from n 5 1151 for sesame to n 5 1170 for egg).
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toward greater rates of nonadherence being associated with
more significant eczema at enrollment (44.7% adherent with no
eczema, 37.4% with mild SCORAD, 29.6% with moderate
SCORAD, and 0%with severe SCORAD; P5 .01, test for trend).
However, the strongest univariate association with EIG nonadher-
ence was shown with ethnicity: white, 44.3% (206/465); mixed,
32.4% (12/37); and Asian/black/
Chinese, 13.3% (4/30; P < .001). Adherence to the early
introduction regimen in the EIG did not differ significantly by
enrollment sensitization status using a threshold of 0.1 kU/L or
greater: 37.8% of sensitized EIG participants were adherent
compared with 43.5% of nonsensitized EIG participants
(P 5 .36).
When eczema at enrollment, ethnicity, and sensitization at
enrollment (whether determined based on results of skin prick
testing or specific IgE measurement) were included in a logistical
model with EIG adherence as the outcome, only ethnicity
remained significant (data not shown).Efficacy of the early introduction regimen among
groups at high risk of food allergy
Enrollment eczema. In an intention-to-treat analysis of
infants with any visible eczema at the enrollment visit, there were
reductions in the EIG for allergy to 1 or more foods (SIG, 18.2%;
EIG, 15.6%; P 5 .56), egg allergy (SIG, 14.0%; EIG, 9.8%;
P 5 .27), and peanut allergy (SIG, 7.0%; EIG, 2.8%; P 5 .10),
with the latter approaching statistical significance.
Analysis of intention-to-treat efficacy among infants with
visible eczema categorized by grouped eczema severity status
(SCORAD), see Fig 1, showed efficacy in the EIG infants with
moderate SCORAD eczema for the outcome of allergy to 1 or
more foods (SIG, 46.7%; EIG, 22.6%; P 5 .048) and for egg al-
lergy (SIG, 43.3%; EIG, 16.1%; P 5 .02). There was also a
79% reduction in peanut allergy in the mild SCORAD group
(SIG, 4.5%; EIG, 0.9%), but it was not statistically significant
(P 5 .21). Results of formal statistical interaction tests between
study group and grouped SCORAD were not significant.
However, when analyzing SCORAD as a continuous variable,
there was a statistically significant interaction effect for theassociation between study group and continuous SCORAD for
egg allergy (interaction term OR, 0.95; P 5 .028).
There were too few participants with severe SCORAD eczema
for statistical comparisons between the 2 study groups to be
robust. If the groups with moderate and severe SCORAD were
combined, the risk reduction was similar to that of the moderate
SCORAD group alone, and the significance test remained statis-
tically significant for egg (P 5 .02) but was of borderline signif-
icance for the primary outcome (P 5 .07).
Ethnicity. Despite the very low rates of adherence in the
Asian, black, or Chinese infants in the EIG, rates of food allergy
in the EIG were lower in 8 of the 9 comparisons within
ethnic groups in Fig 2. However, there were no statistically
significant intention-to-treat effects for any of the food allergy
outcomes.
In contrast, allergy to 1 or more foods showed a stepwise
increase fromwhite participants (both groups combined, 5.3%) to
mixed ethnicity (9.4%), with the highest prevalence being
observed in Asian, black, or Chinese participants (19.3%,
P < .0005). The same pattern is seen in Fig 2 within the SIG
(P 5 .03) and the EIG (P 5 .001) separately.
Infants sensitized at enrollment. For more information
on infants sensitized (>_0.1 kU/L) at enrollment, see Fig 3. The
primary outcome, allergy to 1 or more foods, could be determined
in 89% (1045/1170) of participants with enrollment IgE
sensitization data to 1 or more foods. Peanut allergy status could
be determined in 89% (1041/1166) of those with enrollment
peanut IgE sensitization data and egg allergy status in 89%
(1045/1170) of those with enrollment egg IgE sensitization data.
Of the 157 infants who were sensitized to 1 or more foods
(>_0.1 kU/L) whose primary outcome status was evaluable, 34.2%
(27/79) of SIG participants developed food allergy to 1 or more
foods versus 19.2% (15/78) of EIG participants (P5 .03). Thirty-
nine infants were sensitized to peanut at 0.1 kU/L or greater, and
the corresponding figures for developing a peanut allergy in in-
fants whose peanut allergy status was evaluable were as follows:
33.3% (6/18) for SIG infants versus 14.3% (3/21) for EIG infants
(P 5 .26). Sixty-seven infants were sensitized to egg at 0.1 kU/L
or greater; egg allergy developed in thosewhose egg allergy status
was evaluable in 48.6% (18/37) of SIG infants versus 20.0% (6/
30) of EIG infants (P 5 .01). Adjusting for age, ethnicity, sex,
and maternal age did not affect the results.
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FIG 1. Intention-to-treat efficacy of the EAT study by enrollment eczema SCORAD score group.
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sensitization was significant for egg (interaction term P 5 .041)
but not for peanut (P 5 .673) or sensitization to 1 or more foods
(P 5 .149).
Among infants with no enrollment sensitization to any food or
specifically to peanut or egg, there were no significant differences
in food allergy rates between the 2 groups. Similarly, among those
without enrollment IgE data, there were no significant differences
between the 2 groups in the intention-to-treat analysis.
No sample was available to measure specific IgE levels in 133
participants at 3months of age (74 SIG and 59 EIG infants). Being
in this group was not associated with ethnic status, visible eczema
at enrollment, or the presence of sensitization on skin prick tests.
A sensitivity analysis was undertaken, apportioning those infants
with IgE data missing to the sensitized or nonsensitized groups in
accordancewith the prevalence of sensitization in thosewith data.
The efficacy of the intervention for egg persisted, and the formal
interaction test remained statistically significant.
There are no existing data on allergen-specific IgE levels or
skin prick test responses as predictors of challenge-proved food
allergy in 3-month-old infants. Only 7 of the 652 EIG infants had
positive enrollment food challenge results (milk, 4; egg, 2;
peanut, 2; and wheat, 1). These numbers are too small to generate
positive predictive values in this age group.DISCUSSION
A recent systematic review of all published early intervention
trials undertaken to date concluded that early egg or peanut
introduction to the infant diet was associated with lower risk of
developing egg or peanut allergy.12
The LEAP study showed a very strong intention-to-treat
effect. However, this was in the context of an extremely high
per-protocol adherence rate (96%), which was achieved
through regular sustained contact with the families. The EAT
study intervention was considerably more challenging, with
multiple foods being introduced at a young age. This, com-
bined with a more pragmatic contacting regimen, had a
concomitant effect of significantly reducing the per-protocol
adherence rate.
In this article we have shown that despite significantly lower
adherence rates than in the LEAP study, groups of infants at high
risk of developing a food allergy, including those sensitized at
enrollment and thosewith increasing eczema severity (SCORAD)
benefited from early introduction of allergenic solids. Of equal
importancewas that early introduction of allergenic foods into the
diets of the non–high-risk infants was not associated with any
increased risk of food allergy.
It is important to note that we investigated the efficacy of the
EAT intervention in these groups of infants because they are
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FIG 2. Intention-to-treat efficacy of the EAT study by ethnicity.
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PERKIN ET AL 1611known to be at particularly high risk of developing a food
allergy. Not all of these groups are readily identifiable: infants
with nonwhite ethnicity and those with visible eczema are, and
hence could benefit from targeted support with recommenda-
tions for early food introduction. Conversely, although we are
not proposing IgE screening in the general population fromwhich the EAT study population was recruited, it is of
significance that EAT study early food intervention is being
shown to have been effective in an intention-to-treat analysis in
this group of infants.
Current National Institute of Allergy and Infectious Diseases
guidelines propose introduction of peanut from around 6 months
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FIG 3. Intention-to-treat efficacy of the EAT study among infants sensitized (IgE >_0.1 kU/L) at enrollment.
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1612 PERKIN ET ALof age in children with mild-to-moderate eczema.13 In the
guidelines the authors state that their recommendation is based
on 2 pieces of evidence: first, evidence from the LEAP study, in
that some infants who participated in the LEAP study based on
an egg allergy had a SCORAD at screening in the mild-to-
moderate category, and second, the per-protocol protective effectseen with early peanut introduction in the EAT study.13 Of interest
is our identification of a significant intention-to-treat effect in
children with moderate eczema (52% reduction in allergy to >_1
foods and 63% reduction in egg allergy) and with increasing
eczema SCORAD for egg allergy. This adds to the evidence pre-
sented in these guidelines.
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analysis of the efficacy of the early introduction intervention in
infants with eczema at enrollment was stipulated a priori.
Investigating the effects of the intervention in sensitized infants
and nonwhite infants are post hoc subgroup analyses that are
subject to well-recognized limitations. If important subgroup
effects are anticipated, trials should either be powered to detect
them reliably, or pooled analyses of several trials should be
undertaken.14
A further limitation is the low adherence rate in the EAT study,
reducing the power to detect an ITT intervention effect in the EAT
study. We have explored in detail which factors are associated
with low adherence in the EAT cohort. In that publication we
modelled the effect of improving adherence in the groups at high
risk of developing a food allergy (nonwhite participants and those
with early-onset eczema) and showed that this has the potential to
significantly reduce the burden of food allergy if sufficiently high
adherence were able to be achieved.15
The EAT study intervention did not show intention-to-treat
efficacy when children with visible eczemawere considered as one
group, but efficacy was present within the moderate SCORAD
subgroup and with continuous SCORAD for egg allergy. The
number of infants with severe SCORAD eczema in the EAT study
was too small to draw any conclusions about the efficacy of the
interventionwithin this subgroupwithin the EAT study.We discuss
the reasons for this in the Discussion section in this article’s Online
Repository at www.jacionline.org.
In the LEAP study, peanut-specific IgE levels of 0.1 kU/L or
greater in infancy were clinically and statistically significant in
terms of predicting peanut allergy at 60 months of age. Overall,
75% (48/64) of cases of peanut allergy in the LEAP study came
from those with peanut-specific IgE levels of 0.1 kU/L or greater
at baseline, and in the avoidance group this number was 74%
(40/54). In LEAP participants who had egg allergy with mild or
no eczema at enrollment, the proportion developing peanut
allergy, with IgE levels to peanut of 0.1 kU/L or greater at
baseline, was 89% (8/9) overall and 88% (7/8) in the avoidance
group (the P value for this subgroup analysis within the mild
eczema group [n 5 105] was significant: P 5 .0002). The
clinical significance of this threshold was confirmed in the
EAT study, with 69% of those developing a food allergy in the
SIG by 3 years of age already having specific IgE present to 1
or more of the early introduction foods at the 0.1 kU/L
threshold at 3 months of age.
As countries, including the United States,16 Australia,17 and
the United Kingdom,18,19 move to issue new infant feeding guide-
lines in light of EATand LEAP study findings, as well as the other
randomized trials that have taken place of early food introduction,
we hope our findings will inform the debate as to whether a
risk-based dietary intervention should be recommended or a
population-based intervention should be undertaken.
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Clinical implications: The EAT study was effective in certain
groups of infants at high risk of developing food allergy in an
intention-to-treat analysis, with significant implications for
new infant feeding recommendations.REFERENCES
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DISCUSSION
The LEAP study has clearly shown that infants with severe
eczema benefit significantly from early peanut introduction.E1 In
the EAT study protocol, a priori, we predicted that 25% of infants
would have visible eczema at the 3-month assessment, and we
estimated the prevalence of food allergy in these infants to be
30%.E2 By using this estimate, the study had 99% power to
show a reduction from 30% to 10% in food allergy and 85%
power to detect a reduction from 30% in the SIG to 15% in the
EIG.E2 However, although the estimate of the proportion of
infants with any visible eczema at enrollment was accurate
(24.4%), the rate of any food allergy in the SIG infants with
visible eczema at enrollment was significantly lower than
anticipated (18.2% as opposed to 30%). This reflects the
preponderance of mild eczema among those with visible eczema
REFERENCES
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at enrollment and meant that the study was potentially under-
powered to explore eczema subgroup efficacy. The fact that we
found significant findings despite this is noteworthy. Furthermore,
we are now undertaking a case-based pooled analysis of several of
the early food introduction trials to optimally investigate the
efficacy of early food introduction in these subgroups.E3
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1319 Parcipants were screened for EAT study
16 ineligible for enrollment: major health 
concerns idenﬁed from blood test 
results/clinical ﬁndings*
1303 eligible infants enrolled in study
652 Were assigned to the
Early Introducon Group
651 Were assigned to the 
Standard Introducon Group
567 Were included 
in the ITT analysis
595 Were included
in the ITT analysis
56 Had missing data on outcomes
7 Exceeded visit window at ﬁnal visit
6 Could not be evaluated by means of 
diagnosc algorithm
43 Withdrew voluntarily†
85 Had missing data on outcomes
9 Exceeded visit window at ﬁnal visit
7 Could not be evaluated by means of 
diagnosc algorithm 
69 Withdrew voluntarily†
31 Had missing data on SIG 
adherence criteria
SIG Adherence non-evaluable
81 Had missing data on EIG 
adherence criteria
EIG Adherence non-evaluable
564 Were evaluable
for per-protocol adherence
524
SIG Per-Protocol
40
SIG Non Per-Protocol
486 Were evaluable
for per-protocol adherence
208
EIG Per-Protocol
278
EIG Non Per-Protocol
FIG E1. EAT enrollment and randomization. Baseline visits occurred when participants were 3 months of
age. *Eight infants randomized to each group were found to have significant health issues either on blood
testing or on clinical examination at the enrollment visit, rendering them ineligible for enrollment:
conditions included severe vitamin D deficiency, severe iron deficiency, severe failure to thrive, familial
hypercholesterolemia, congenital stridor, epidermolysis bullosa, and cartilage-hair hypoplasia syndrome.
Forty-three participants in the SIG and 69 participants in the EIG withdrew voluntarily from the study.
Reasons given were as follows: concerns about blood tests (SIG, 0; EIG, 2), emigration (SIG, 10; EIG, 12),
expenses (SIG, 1; EIG, 1), family health issues (SIG, 3; EIG, 0), family issues (SIG, 2; EIG, 4), no reason given
(SIG, 11; EIG, 16), lost contact with family (SIG, 15; EIG, 28), too far to travel for study assessments (SIG, 0;
EIG, 1), and unhappy participating in the study (SIG, 1; EIG, 5).
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